3/20
11:06 am
scph
scPharmaceuticals Inc. (NASDAQ: SCPH) had its price target lowered by analysts at Maxim Group from $20.00 to $12.00. They now have a "buy" rating on the stock.
Low
Report
scPharmaceuticals Inc. (NASDAQ: SCPH) had its price target lowered by analysts at Maxim Group from $20.00 to $12.00. They now have a "buy" rating on the stock.
3/20
08:05 am
scph
scPharmaceuticals Inc. (NASDAQ: SCPH) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.
Medium
Report
scPharmaceuticals Inc. (NASDAQ: SCPH) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.
3/19
04:01 pm
scph
scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Medium
Report
scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
3/12
04:01 pm
scph
scPharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on Wednesday, March 19, 2025
Low
Report
scPharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on Wednesday, March 19, 2025
3/6
04:01 pm
scph
scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX® Indication to Include the Treatment of Edema in Patients with Chronic Kidney Disease
High
Report
scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX® Indication to Include the Treatment of Edema in Patients with Chronic Kidney Disease
3/5
12:00 pm
scph
ScPharmaceuticals, Inc. (SCPH) Expected to Beat Earnings Estimates: Should You Buy? [Yahoo! Finance]
Low
Report
ScPharmaceuticals, Inc. (SCPH) Expected to Beat Earnings Estimates: Should You Buy? [Yahoo! Finance]
3/3
08:10 am
scph
scPharmaceuticals Inc. (NASDAQ: SCPH) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.
Medium
Report
scPharmaceuticals Inc. (NASDAQ: SCPH) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.
2/26
04:01 pm
scph
scPharmaceuticals Announces Participation in Two Upcoming Investor Conferences
Low
Report
scPharmaceuticals Announces Participation in Two Upcoming Investor Conferences
2/5
04:01 pm
scph
scPharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Medium
Report
scPharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
1/10
08:00 am
scph
scPharmaceuticals Provides Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results
Medium
Report
scPharmaceuticals Provides Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results